Using a pulmonary artery catheter and early carvedilol treatment for cardiogenic shock in heart failure patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effects of hemodynamic monitoring using a pulmonary artery catheter on survival rates and the reduction of inotropic agents in patients experiencing cardiogenic shock due to heart failure with reduced ejection fraction (HFrEF). It will compare outcomes between patients receiving this monitoring and those who do not, focusing on long-term survival based on the timing of beta-blocker initiation. The study addresses a critical gap in prospective research regarding monitoring indicators and treatment goals in this high-mortality condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults age 19 and above ( no age limit for elderly )
* Patients with cardiogenic shock requiring intensive care monitoring in ICU
* Patients eligible for oral medication administration
* Patients who have provided research participation consent through a written informed consent form

Exclusion Criteria:

* Unwilling or unable to obtain informed consent by the participant or substitute decision maker
* Patients with mechanical circulatory support at the time of screening
* Patients with acute coronary syndrome
* Patients with severe valvular heart disease requiring emergent percutaneous procedures or surgery
* Known hypersensitivity to beta-blockers
* Patients with a history of bronchospasm or asthma
* Patients with bradycardia or second or third-degree atrioventricular block
* Patients with sick sinus syndrome, including sinoatrial block
* Patients with untreated pheochromocytoma
* Patients currently undergoing de-sensitization therapy
* Patients who are currently pregnant, postpartum period within 30 days or breast-feeding

Where it's running

• Asan Medical Center
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Min-Seok Kim, PhD
• Email: msk@amc.seoul.kr
• Phone: 82-2-3010-3948

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Factors Influencing Outcomes in ECMO and Impella Patients

  This study tests whether metabolic and thyroid hormone changes help predict survival for adults on ECMO or Impella at a single Hungarian cardiac ICU.

  Recruiting Gottsegen National Cardiovascular Institute · Budapest · NCT07885618

• Evaluating a noninvasive tissue sensor to detect cardiogenic shock earlier in heart patients

  This pilot, noninvasive study tests whether the NIRSense wearable can help detect deterioration in adults with cardiogenic shock risk due to heart attack or heart failure.

  Recruiting NIRSense Inc. · Weston, Florida · NCT07825363

• Yoga-based cardiac rehabilitation for heart failure with reduced ejection fraction

  This trial tests whether a yoga-based rehabilitation program can help people with heart failure and reduced ejection fraction compared with an educational program.

  Recruiting at 12 sites Centre for Chronic Disease Control, India · Dharwad, Karnataka and 15 other locations · NCT07817589

• Safety and Efficacy of an Extracorporeal Ventricular Assist System for Cardiogenic Shock

  This study tests whether an extracorporeal ventricular assist device can safely provide short-term heart support and help patients with cardiogenic shock or trouble weaning from bypass.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07769528

• Left Ventricular Support and Advanced Monitoring in AMI–Cardiogenic Shock: Immediate Impella Use and PAC/Monitoring vs Standard Care

  In adults with heart attack-related cardiogenic shock, this trial tests whether using an Impella left ventricular assist device and/or protocolized pulmonary artery catheter monitoring improves survival compared with standard care.

  Recruiting Leipzig Heart Science gGmbH · Leipzig, Saxony · NCT07762560

• Lumacaftor to improve cerebral blood flow in heart failure with reduced ejection fraction

  This study tests whether lumacaftor can improve brain blood flow and thinking abilities in adults with a certain type of heart failure.

  Recruiting Phase 2 Qanatpharma AG · Toronto, Ontario and 1 other locations · NCT07695090

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.